NCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
11 trialsNCT04420975 2026-03-10
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03628209 2026-02-05
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04416568 2025-12-17
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03449108 2025-11-21
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04551430 2025-11-12
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05836571 2025-10-20
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04095208 2025-10-02
CONGRATS
Institut Bergonié
Phase 2 Active not recruiting
NCT03282344 2025-10-01
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03463408 2025-08-11
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
University of Rochester
Phase EARLY_PHASE1 Active not recruiting
NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting